<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kubota A</submitter><funding>KAKEN</funding><funding>Kaken Pharmaceutical (Japan)</funding><funding>National Institute for Environmental Studies, Japan</funding><pagination>3448</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10970325</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>25(6)</volume><pubmed_abstract>Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and its treatment varies widely; however, when inflammation is high, a complete nutrient containing pre-digested elemental diet (ED) is used to preserve the intestinal tract. In this study, we investigated the mechanisms underlying the effectiveness of EDs for IBD using mice. C57BL/6 mice were orally treated with the ED (5 mL/day) and its ingredient L-tryptophan (Trp) (1-100 mg/kg), respectively. Flow cytometry analysis revealed that treatment with the ED and Trp (10 and 100 mg/kg) significantly increased the percentage of splenic CD4+-/CD25+-/Foxp3+ regulatory T cells (Tregs). In the 2% DSS-induced colitis-mouse model, Trp administration (100 mg/kg) led to a significant decrease in TNF-α and increase in IL-10 in the serum as well as a significant decrease in the inflammation score. Furthermore, the aryl hydrocarbon receptor (AhR) agonistic activity, which is a key function of Treg induction, of Trp and 15 Trp metabolites was characterized using a highly sensitive DR-EcoScreen cell assay. Five Trp metabolites, including L-kynurenine, acted as AhR agonists, while Trp did not. Taken together, these results suggest that the ED treatment has a Trp-dependent immunoregulatory effect, and several Trp metabolites that activate the AhR might contribute to induction of remission in patients with IBD.</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Immunoregulatory Effects of Elemental Diet and Its Ingredient, Tryptophan, via Activation of the Aryl Hydrocarbon Receptor in Mice.</pubmed_title><pmcid>PMC10970325</pmcid><funding_grant_id>1620AA041</funding_grant_id><funding_grant_id>23K11454</funding_grant_id><funding_grant_id>21K14821</funding_grant_id><pubmed_authors>Imai S</pubmed_authors><pubmed_authors>Kojima H</pubmed_authors><pubmed_authors>Murase W</pubmed_authors><pubmed_authors>Terasaki M</pubmed_authors><pubmed_authors>Sugawara M</pubmed_authors><pubmed_authors>Takekuma Y</pubmed_authors><pubmed_authors>Kubota A</pubmed_authors><pubmed_authors>Aoyagi R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Immunoregulatory Effects of Elemental Diet and Its Ingredient, Tryptophan, via Activation of the Aryl Hydrocarbon Receptor in Mice.</name><description>Inflammatory bowel disease (IBD) is characterized by chronic intestinal inflammation and its treatment varies widely; however, when inflammation is high, a complete nutrient containing pre-digested elemental diet (ED) is used to preserve the intestinal tract. In this study, we investigated the mechanisms underlying the effectiveness of EDs for IBD using mice. C57BL/6 mice were orally treated with the ED (5 mL/day) and its ingredient L-tryptophan (Trp) (1-100 mg/kg), respectively. Flow cytometry analysis revealed that treatment with the ED and Trp (10 and 100 mg/kg) significantly increased the percentage of splenic CD4+-/CD25+-/Foxp3+ regulatory T cells (Tregs). In the 2% DSS-induced colitis-mouse model, Trp administration (100 mg/kg) led to a significant decrease in TNF-α and increase in IL-10 in the serum as well as a significant decrease in the inflammation score. Furthermore, the aryl hydrocarbon receptor (AhR) agonistic activity, which is a key function of Treg induction, of Trp and 15 Trp metabolites was characterized using a highly sensitive DR-EcoScreen cell assay. Five Trp metabolites, including L-kynurenine, acted as AhR agonists, while Trp did not. Taken together, these results suggest that the ED treatment has a Trp-dependent immunoregulatory effect, and several Trp metabolites that activate the AhR might contribute to induction of remission in patients with IBD.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2025-04-21T21:28:52.512Z</modification><creation>2025-04-05T18:22:43.616Z</creation></dates><accession>S-EPMC10970325</accession><cross_references><pubmed>38542428</pubmed><doi>10.3390/ijms25063448</doi></cross_references></HashMap>